title: The ELR+CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma.
abstract: The long-term efficacy of anti-angiogenesis drugs targeting vascular endothelial growth factor (VEGF) and VEGF receptors in the treatment of renal cell carcinoma (RCC) has been lacking. We have shown that the ELR+CXCL cytokines and their (C-X-C) chemokine receptors, namely CXCR1 and CXCR2, stimulate cancer cell proliferation, tumor inflammation, and angiogenesis. Hence, this essential molecular nexus regulating cancer growth represents a key therapeutic target.
authors: University of Nice Sophia Antipolis; UMR CNRS 7284/U INSERM 1081; Nice, France.
authors: Sandy
authors: S
authors: Giuliano
authors: University of Nice Sophia Antipolis; UMR CNRS 7284/U INSERM 1081; Nice, France.
authors: Mélanie
authors: M
authors: Guyot
authors: Centre Scientifique de Monaco; Monaco.
authors: Renaud
authors: R
authors: Grépin
authors: University of Nice Sophia Antipolis; UMR CNRS 7284/U INSERM 1081; Nice, France.
authors: Gilles
authors: G
authors: Pagès
keywords: CXCL7; CXCR1; CXCR2; ELR+CXCL; angiogenesis; inflammation; renal cell carcinoma